No Data
No Data
Smart Hong Kong stock buyback statistics | September 12th
Hong Kong stock buyback statistics | September 12th
Institutions Along With Individual Investors Who Hold Considerable Shares InCSPC Pharmaceutical Group Limited (HKG:1093) Come Under Pressure; Lose 6.2% of Holdings Value
cspc pharma spent 29.5918 million Hong Kong dollars to repurchase 6.45 million shares on September 10th.
cspc pharma (01093.HK) announced that on September 10, 2024, it spent 29.5918 million Hong Kong dollars to repurchase 6.45 million shares at a repurchase price of 4.56-4.61 Hong Kong dollars per share.
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
CSPC Pharma (01093.HK) received Chairman Cai Dongchen's shareholding of 1 million shares.
According to the latest equity disclosure data from the Hong Kong Stock Exchange on September 10, 2024, cspc pharma (01093.HK) was observed to have its executive director and chairman, Cai Dongchen, increasing his shareholding by an average of HK$4.612 per share, purchasing 1 million shares for a total investment of approximately HK$4.612 million. Following the shareholding increase, Cai Dongchen's latest shareholding count is 2,851,333,670 shares, and the shareholding ratio has increased from 24.03% to 24.04%.
CSPC Pharma (01093.HK): Arpitan Injection receives pharmaceutical registration approval.
CSPC Pharma (01093.HK) announced on September 9th that its developed Aprepitant injection (18ml:130mg) has obtained the drug registration approval from China's National Medical Products Administration. This product is a submicron emulsion injection of NK1 receptor antagonist, which can selectively bind to and antagonize P substance in the brain, effectively preventing acute and delayed vomiting. It is suitable for adult patients to prevent nausea and vomiting caused by highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC). Compared with the oral formulation already on the market, this product can
No Data